Multiple sclerosis symptoms improved by new cellular immunotherapy

A new cellular immunotherapy treatment that targets the Epstein-Barr virus (EBV) has been shown to improve the symptoms and quality of life for people with multiple sclerosis (MS) in a recent Phase I clinical trial. Results of an open-label, Phase I clinical trial conducted at the University of Queensland (Brisbane, Australia), have shown that a new cellular immunotherapy improves the symptoms of multiple sclerosis for the majority of patients. This represents the first time a T-cell immunotherapy has been used to treat an autoimmune disease and could potentially help change the lives of those with MS in the future. The...